Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

Matthew Galsky, MD
Published: Tuesday, Nov 14, 2017



Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.

The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.
 
SELECTED
LANGUAGE


Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.

The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x